Design, synthesis and preclinical evaluation of radiolabeled peptides for diagnosis and therapy.
Recent years have seen an increased effort in the development of peptide based radiopharmaceuticals for nuclear medicine applications in imaging and therapy. This field is of particular interest in the development of new cancer imaging and treatment strategies. Major developments in the molecular biology of cancer have brought forth the discovery of a number of receptor systems and other cell surface molecules that can be utilized as molecular targets for peptide based agents. Although such a strategy is very appealing and shows great potential for application in humans, there are as yet very few radiopharmaceuticals developed based on this scheme that have made it into clinical practice. Many different factors contribute to the generation of a successful radiopharmaceutical. Among these, a thorough and efficient pre-clinical evaluation process is necessary to single out those lead compounds that show more promise and are most likely to be winners in clinical applications. To maximize the efficacy of pre-clinical testing one must utilize currently available technology to the best extent possible. Expertise in different areas of drug development is indispensable for this type of research. This work will analyze currently available methods utilized to evaluate radiopharmaceuticals being developed, from compound design to evaluation in pre-clinical animal models.
Aloj
L
L
UOC Medicina Nucleare, Istituto Nazionale Tumori, Fondazione G Pascale, Via M Semmola, 80131-Napoli-Italy. luigaloj@unina.it
Morelli
G
G
D000818:Animals; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D009374:Neoplasms, Experimental / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D010446:Peptide Fragments / Q000138:chemical synthesis / Q000627:therapeutic use; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000138:chemical synthesis / Q000627:therapeutic use
D010446:Peptide Fragments; D019275:Radiopharmaceuticals